Lixisenatide
From PeptidePlaza, the free peptide reference · Entry #1199 · Metabolic · Sources fetched 2026-09-11 · Editorial standards
Lixisenatide (also known as Adlyxin, Lyxumia, ZP10A peptide, AVE 0010) is a metabolic research peptide. Lixisenatide, also known as Adlyxin, is a glucagon-like peptide-1 (GLP-1) receptor agonist used to improve glycemic control in adults with type 2 diabetes mellitus.
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that works by mimicking the effects of natural incretin hormones, which play a role in glucose metabolism. It is FDA-approved as an adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes mellitus, often in combination with insulin glargine as Soliqua 100/33. Research also explores its potential in conditions such as acute coronary syndrome, Parkinson's disease, and type 1 diabetes. The literature frequently discusses its role among GLP-1 receptor agonists in managing type 2 diabetes and its emerging applications in obesity and neurological disorders.
1 Mechanism of action
Glucagon-like peptide 1 receptor agonist (agonist)
Primary targets: Glucagon-like peptide 1 receptor
2 Reported effects
Effects below are those reported in the published literature cited on this page. They are not claims of clinical benefit and not medical advice.
2.1 Indicated / studied for
- Diabetes Mellitus, Type 2
2.2 Side effects
- Hypoglycemia
- Nausea
- Nasopharyngitis
- Diarrhea
- Upper respiratory tract infection
- Headache
3 Chemical and physical properties
| CAS number | 320367-13-3 |
|---|---|
| Molar mass | 4858 g/mol |
| Purity (typical) | Not independently verified |
| Half-life | ~3 hours |
| Brand names | Soliqua 100/33 |
| Route | SUBCUTANEOUS |
| Storage | −20 °C, lyophilised powder, desiccated |
| Solubility | Sterile water / bacteriostatic water |
| Receptors / targets | Glucagon-like peptide 1 receptor |
3.1 Amino acid sequence
His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Ser-Lys-Lys-Lys-Lys-Lys-Lys-NH2
4 Research dosages
15 units to 60 units SC once daily within the hour prior to the first meal
5 Research studies (8)
- GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Molecular metabolism (2021) · Review - Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials
International journal of molecular sciences (2023) · Review - Trial of Lixisenatide in Early Parkinson's Disease
The New England journal of medicine (2024) · RCT - GLP-1 Receptor Agonists: A New Treatment in Parkinson's Disease
International journal of molecular sciences (2024) · Review - Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo-controlled clinical trials
Diabetes, obesity & metabolism (2025) · Systematic Review - Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
The New England journal of medicine (2015) · RCT - GLP-1 receptor agonists: an updated review of head-to-head clinical studies
Therapeutic advances in endocrinology and metabolism (2021) · Review - Lixisenatide
(2006) · Review
6 Safety and risk profile
6.1 Regulatory status
Lixisenatide is currently classified as FDA approved. Approval applies to specific clinical indications and dosing; research-grade material is not the approved product.
6.2 Contraindications
Conditions and populations in which use is contraindicated:
- During episodes of hypoglycemia
- Serious hypersensitivity to insulin glargine, lixisenatide, or any excipients in Soliqua 100/33
6.3 Drug interactions
| Drug or class | Interaction | Risk |
|---|---|---|
| Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs, sulfonamide antibiotics | Increased risk of hypoglycemia | High |
| Atypical antipsychotics, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens, protease inhibitors, somatropin, sympathomimetic agents, thyroid hormones | Decreased blood glucose lowering effect | High |
| Alcohol, beta-blockers, clonidine, lithium salts | Increased or decreased blood glucose lowering effect | Moderate |
| Antiadrenergic Drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine) | Reduced signs and symptoms of hypoglycemia | Moderate |
| Oral medications (e.g., oral contraceptives, antibiotics, acetaminophen) | Delayed absorption due to delayed gastric emptying | Moderate |
6.4 Long-term risks
- Anaphylaxis and Serious Hypersensitivity Reactions
- Acute Pancreatitis
- Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen
- Acute kidney injury Due to Volume Depletion
- Hypokalemia
6.5 Research best practices
- Store in a refrigerator, 36°F–46°F (2°C–8°C) prior to first use
- Do not freeze
- Protect from light
- Store at room temperature up to 77°F (25°C) after first use
7 Frequently asked questions
- What is Lixisenatide used for?
- Lixisenatide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is often used in combination with insulin glargine, marketed as Soliqua 100/33.
- How does Lixisenatide work?
- Lixisenatide functions as a glucagon-like peptide-1 (GLP-1) receptor agonist. It activates GLP-1 receptors, which helps to regulate blood glucose levels by influencing insulin secretion and gastric emptying.
- Is Lixisenatide FDA approved?
- Yes, Lixisenatide received FDA approval in 2013. It is marketed under names such as Adlyxin and as part of the combination product Soliqua 100/33.
- What are the common side effects of Lixisenatide?
- Common adverse reactions reported in patients treated with Lixisenatide, particularly as Soliqua 100/33, include hypoglycemia, nausea, nasopharyngitis, diarrhea, upper respiratory tract infection, and headache.
- What are the contraindications for Lixisenatide?
- Lixisenatide is contraindicated during episodes of hypoglycemia and in patients with serious hypersensitivity to insulin glargine, lixisenatide, or any of the excipients in Soliqua 100/33.
8 References
- Lixisenatide — compound summary PubChem. View source
- Lixisenatide — molecule record ChEMBL. View source
- Lixisenatide — FDA approved prescribing information U.S. Food and Drug Administration. View source
- Lixisenatide — published literature (728 records) PubMed. View source
Related compounds
Entries that share a target, a mechanism, or a research area with Lixisenatide.
Also targets Glucagon-like peptide 1 receptor
Dulaglutide, marketed as TRULICITY, is a glucagon-like peptide-1 (GLP-1) receptor agonist used to improve glycemic control and reduce cardiovascular risk in adults with type 2 diabetes mellitus.
Also targets Glucagon-like peptide 1 receptor
Albiglutide is a glucagon-like peptide 1 (GLP-1) receptor agonist used in the treatment of type 2 diabetes mellitus.
Also targets Glucagon-like peptide 1 receptor
Taspoglutide is a glucagon-like peptide 1 receptor agonist that was investigated for the treatment of Type 2 Diabetes Mellitus.
Also metabolic
Elsiglutide is a glucagon-like peptide 2 receptor agonist currently in Phase 2 clinical trials for the treatment of diarrhea.